Figure 4
Combined treatment of mice with a trifunctional bsAb and DCs is superior to treatment with bsAb alone. (A) All mice were inoculated with a lethal challenge of 1 × 105 B78-D14 cells intraperitoneally on d 0. Mice were treated with 10 µg Surek alone or combined with 5 × 105 DCs on d 2 and 10, administered intraperitoneally. A control group was treated with DCs alone. For blocking of FcR function, the mAb 4G8 was given intraperitoneally on d 1, 9 and 16. Tumor control groups received no treatment. Surviving mice treated with DCs and Surek received a rechallenge with a lethal dose of B16F0 melanoma cells on d 200, indicated by the arrow. (B) All mice were inoculated with a lethal challenge of 5 × 103 B16-EpCAM cells intraperitoneally on d 0, which are not recognized by Surek. Therapy was done as shown in (A). Typical results from three therapy experiments are shown.